Fremanezumab
NERVOUS SYSTEM
Also known as: ajovy, fremanezumab (genetical recombination), fremanezumab-vfrm, LBR-101, PF-04472429, RN307, TEV-48125
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Fremanezumab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 1 molecular target, including CALCA. Recorded indications include Migraine and Prevention of migraine attacks.
- Molecular targets: CALCA (1 listed in DrugCentral).
- Indications: Migraine and Prevention of migraine attacks.
- ATC code: N02CD03 (Calcitonin gene-related peptide (CGRP) antagonists).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Migraine
- Prevention of migraine attacks
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Calcitonin gene-related peptide 1 | CALCA | other | Kd 10.30 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2021-06-23 | PMDA | — | OTSUKA PHARMACEUTICAL Co., Ltd. | |
| 2019-03-28 | EMA | — | TEVA GMBH | |
| 2018-09-14 | FDA | — | TEVA PHARMS USA |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N02CD03 | NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Injection site erythema | 456.4 |
| Accidental exposure to product | 451.7 |
| Injection site pruritus | 347.4 |
| Injection site rash | 332.4 |
| Injection site reaction | 287.5 |
| Injection site swelling | 285.9 |
| Injection site pain | 285.7 |
| Device leakage | 172.7 |
| Migraine | 169.9 |
| Incorrect dose administered by device | 146.1 |
| Device malfunction | 134.7 |
| Drug dose omission by device | 132.9 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1655501-53-3 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Fremanezumab used for?
DrugCentral lists the following indications for Fremanezumab: Migraine and Prevention of migraine attacks.
How does Fremanezumab work?
Its molecular targets in DrugCentral include CALCA.
When was Fremanezumab first approved?
Fremanezumab was first approved by the FDA in 2018.
Browse: all drugs starting with F · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5315 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4297756 — compound record and bioactivity
- DrugBank DB14041 — drug record
- FDA UNII PF8K38CG54 — substance identity
- DailyMed: FDA labels for Fremanezumab — current prescribing information (label search)
- UniProt P06881 (CALCA) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.